MedPlus Health IPO to open on Dec 13

Published On 2021-12-07 11:03 GMT | Update On 2021-12-07 11:03 GMT

New Delhi: Pharmacy retail chain MedPlus Health Services on Tuesday fixed a price band of Rs 780-796 a share for its Rs 1,398 crore initial share-sale, which will open for public subscription on December 13.

The three-day initial public offering (IPO) will close on December 15. The bidding for anchor investors will open on December 10

The initial share-sale comprises fresh issuance of equity shares worth 600 crore and an offer for sale (

OFS) of up to equity shares aggregating up to Rs 798.30 crore by promoter and existing shareholders.

The company has cut the OFS size to Rs 798.30 crore from Rs 1,038.71 crore.

The issue includes a reservation of equity shares worth Rs 5 crore for the company's employees who will receive those shares at a discount of Rs 78 per share to final issue price.

Proceeds of the fresh issue will be used for funding working capital requirements of the company's subsidiary, Optival.

Half of the issue size has been reserved for qualified institutional buyers (QIBs), 15 per cent for non-institutional investors and 35 per cent for retail investors.

Investors can bid for a minimum of 18 equity shares and in multiples thereof.

MedPlus was founded in 2006 by Gangadi Madhukar Reddy, who is the company's managing director and chief executive officer.

The Hyderabad-based pharmacy retailer offers a wide range of products, including pharmaceutical and wellness products such as medicines, vitamins, medical devices and test kits, and FMCG products such as home and personal care products, including toiletries, baby care products, soaps and detergents and sanitisers.

Medplus was also the first pharmacy retailer in India to offer an omni-channel platform and continues to scale up its retail store network.

The company maintains a strong focus on scaling up its store network, having grown from operating initial 48 stores in Hyderabad at the conception of the business to operating India's second largest pharmacy retail network of over 2,000 stores distributed across Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal and Maharashtra, as of March 31, 2021.

Axis Capital, Credit Suisse Securities (India), Nomura Financial Advisory and Securities (India) and Edelweiss Financial Services are the book running lead managers to the issue.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

MedPlus Health IPO to open on Dec 13

Similar News

State Drug Alert: 130 Batches Found Not of Standard Quality in June; No Data Received from Delhi, Gujarat, UP

Bayer extends CEO Bill Anderson contract until 2029

Sun Pharma incorporates subsidiary company in China

GSK fails to gain FDA advisers backing for cancer therapy

Sanofi concludes acquisition of Blueprint Medicines

CDSCO Panel Clears AstraZeneca's Datopotamab for Breast Cancer, Seeks Phase IV Trial

Racket manufacturing fake medicines busted, factory owner held

CDSCO Flags 55 Substandard, 4 Spurious Drugs in June Batch Alert, Full List Inside